Metsera, Inc. (MTSR)
| Market Cap | 5.50B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -307.82M |
| Shares Out | 105.28M |
| EPS (ttm) | -5.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,591,792 |
| Open | 52.35 |
| Previous Close | 52.51 |
| Day's Range | 52.20 - 52.84 |
| 52-Week Range | 12.30 - 54.47 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 58.00 (+11.01%) |
| Earnings Date | Jul 28, 2025 |
About MTSR
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MTSR stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 11.01% from the latest price.
News
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...
BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.
Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades
Wedbush continues to see tremendous upside for Apple (AAPL), citing iPhone sales and the new iPhone Air as catalysts. Pfizer's (PFE) acquisition of Metsera (MTSR) sent the obesity drug maker's stock s...
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o...
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move...
Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
Metsera's shareholders could see significant bonuses if certain milestones are reached.
Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight
Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.
This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer
Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.
Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion
Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a cl...
Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug
Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial ...
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, ...
Metsera to Present at Upcoming September Investor Conferences
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability wi...
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a mo...
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-...
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesi...